CAMP4 Raises up to $100 Million in Private Placement to Advance SYNGAP1 Candidate

Rare Daily Staff

CAMP4 Therapeutics said it has entered into definitive securities purchase agreements with institutional and accredited investors for up to $100 million in gross proceeds through a private placement to fund the preclinical and clinical development of its program for neurodevelopmental conditions caused by the SYNGAP1 gene.

New investor Coastlands Capital led the financing, which includes participation from additional new and existing investors Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners, and the SYNGAP Research Fund.

The private placement includes an initial upfront financing of $50 million in gross proceeds from nearly 26.7 million shares of common stock priced at $1.53 per share at the initial closing, as well as 36,361 shares of common stock priced at $1.65 to certain directors, employees, and consultants of CAMP4 at the initial closing. It also included about 6 million pre-funded warrants at $1.53 for each pre-funded warrant sold in place of common stock at the initial closing.

CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds, subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01, an experimental antisense oligonucleotide therapy.

“With this financing, we are well-positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic,” said Josh Mandel-Brehm, president and CEO of CAMP4. “This investment marks a critical milestone as we continue our mission of developing potentially disease-modifying medicines for patients with disorders marked by suboptimal gene expression.”

Concurrently with the financing, James Boylan, Ravi Thadhani, and Paula Ragan resigned from the board of directors. In conjunction, the CAMP4 board of directors appointed Doug Williams as board chair, while former board chair Steven Holtzman will serve as an independent director.

Williams joined the CAMP4 board in March 2025 and brings extensive life science leadership experience to the company. He was previously president of R&D at Sana Biotechnology and the founding president and CEO of Codiak BioSciences. Prior to Sana, Williams served as EVP of R&D at Biogen, and earlier in his career was CEO of ZymoGenetics. He also held leadership roles at Seattle Genetics, Amgen, and Immunex.

Photo: Josh Mandel-Brehm, president and CEO of CAMP4